[SCHEDULE 13D/A] Armata Pharmaceuticals, Inc. SEC Filing
Innoviva and its wholly owned affiliate report that, following transactions described in this Amendment No. 13 to Schedule 13D, the Reporting Persons collectively hold beneficial ownership of 55,467,459 shares of Armata Pharmaceuticals, Inc., representing approximately 83.3% of the issuer's common stock on a fully counted basis. The filing discloses that Innoviva Strategic Opportunities LLC acquired secured debt of the company under an August 11, 2025 credit agreement that provided Armata with a $15,000,000 term loan.
The August 2025 Credit Agreement carries a 14.00% per annum interest rate and matures on January 11, 2029, and is expressly non-convertible. The Reporting Persons continue to hold existing common shares, warrants to acquire 10,653,847 additional shares, and rights to acquire 19,736,843 shares upon conversion of a convertible loan (excluding accrued interest). Except as amended here, prior Schedule 13D disclosures remain in effect.
Innoviva e la sua affiliata interamente controllata comunicano che, a seguito delle operazioni descritte nel presente Emendamento n. 13 al Schedule 13D, le persone che presentano la comunicazione detengono collettivamente la titolarit脿 effettiva di 55,467,459 azioni di Armata Pharmaceuticals, Inc., pari a circa 83,3% del capitale ordinario dell'emittente su base totalmente conteggiata. La comunicazione rivela che Innoviva Strategic Opportunities LLC ha acquisito debito garantito della societ脿 ai sensi di un contratto di credito dell'11 agosto 2025 che ha previsto un prestito a termine di $15,000,000 a favore di Armata.
L'Accordo di Credito di agosto 2025 prevede un tasso di interesse del 14,00% annuo e scade il 11 gennaio 2029, ed 猫 espressamente non convertibile. Le persone che presentano la comunicazione continuano a detenere le azioni ordinarie esistenti, warrant per l'acquisizione di ulteriori 10,653,847 azioni e diritti per acquisire 19,736,843 azioni al momento della conversione di un prestito convertibile (esclusi gli interessi maturati). Salvo quanto qui modificato, restano valide le precedenti divulgazioni nel Schedule 13D.
Innoviva y su filial de propiedad total informan que, tras las operaciones descritas en esta Enmienda n.潞 13 al Schedule 13D, las Personas Informantes poseen conjuntamente la propiedad beneficiaria de 55,467,459 acciones de Armata Pharmaceuticals, Inc., que representan aproximadamente 83,3% del capital social ordinario del emisor en base a recuento total. La presentaci贸n revela que Innoviva Strategic Opportunities LLC adquiri贸 deuda garantizada de la compa帽铆a en virtud de un contrato de cr茅dito de 11 de agosto de 2025 que otorg贸 a Armata un pr茅stamo a plazo de $15,000,000.
El Contrato de Cr茅dito de agosto de 2025 establece un tipo de inter茅s del 14,00% anual y vence el 11 de enero de 2029, y es expresamente no convertible. Las Personas Informantes contin煤an manteniendo acciones ordinarias existentes, warrants para adquirir 10,653,847 acciones adicionales y derechos para adquirir 19,736,843 acciones al convertir un pr茅stamo convertible (excluyendo intereses devengados). Salvo las enmiendas aqu铆 indicadas, permanecen vigentes las divulgaciones anteriores del Schedule 13D.
Innoviva鞕� 攴� 鞝勳暋 於滌瀽 瓿勳棿靷姅 氤� Schedule 13D鞚� Amendment No. 13鞐� 旮办灛霅� 瓯半灅鞐� 霐半澕 氤搓碃鞚胳澊 頃╆硠 55,467,459欤检潣 Armata Pharmaceuticals, Inc. 欤检嫕鞐� 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 氚滍枆須岇偓鞚� 氤错喌欤� 齑濎垬鞚� 鞎� 83.3%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� Innoviva Strategic Opportunities LLC臧� Armata鞐愱矊 $15,000,000鞚� 旮瓣皠雽�於滌潉 鞝滉车頃� 2025雲� 8鞗� 11鞚�鞛� 鞁犾毄瓿勳暯鞐� 霐半澕 須岇偓鞚� 雼措炒攵� 毂勲毳� 鞚胳垬頄堨潓鞚� 瓿奠嫓頃╇媹雼�.
2025雲� 8鞗� 鞁犾毄瓿勳暯鞚� 鞐办澊鞙� 14.00%毳� 鞝侅毄頃橂┌ 毵岅赴電� 2029雲� 1鞗� 11鞚�鞚搓碃 氇呾嫓鞝侅溂搿� 鞝勴櫂 攵堦皜鞛呺媹雼�. 氤搓碃鞚鸽摛鞚� 旮办〈 氤错喌欤�, 於旉皜搿� 10,653,847欤茧ゼ 旆摑頃� 靾� 鞛堧姅 鞗岆煱韸� 氚� 鞝勴櫂順� 雽�於滌潣 鞝勴櫂 鞁� 19,736,843欤茧ゼ 旆摑頃� 甓岆Μ(氚滌儩 鞚挫瀽 鞝滌櫢)毳� 瓿勳啀 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氤� 靾橃爼靹滌棎靹� 雼Μ 氤�瓴诫悳 攵�攵勳潉 鞝滌櫢頃橁碃電� 鞚挫爠鞚� Schedule 13D 瓿奠嫓電� 鞙犿毃頃╇媹雼�.
Innoviva et sa filiale en pleine propri茅t茅 signalent que, suite aux op茅rations d茅crites dans le pr茅sent Amendement n掳13 au Schedule 13D, les personnes d茅clarante d茅tiennent collectivement la propri茅t茅 b茅n茅ficiaire de 55,467,459 actions d'Armata Pharmaceuticals, Inc., repr茅sentant environ 83,3% des actions ordinaires de l'茅metteur sur une base enti猫rement comptabilis茅e. Le d茅p么t r茅v猫le qu'Innoviva Strategic Opportunities LLC a acquis des cr茅ances garanties de la soci茅t茅 en vertu d'un contrat de cr茅dit dat茅 du 11 ao没t 2025 qui a accord茅 脿 Armata un pr锚t 脿 terme de $15,000,000.
Le contrat de cr茅dit d'ao没t 2025 porte un taux d'int茅r锚t de 14,00% par an et arrive 脿 茅ch茅ance le 11 janvier 2029, et il est express茅ment non convertible. Les personnes d茅clarante conservent les actions ordinaires existantes, des warrants permettant d'acqu茅rir 10,653,847 actions suppl茅mentaires et des droits d'acqu茅rir 19,736,843 actions lors de la conversion d'un pr锚t convertible (hors int茅r锚ts courus). Sauf modification apport茅e par les pr茅sentes, les divulgations ant茅rieures au Schedule 13D restent en vigueur.
Innoviva und seine hundertprozentige Tochtergesellschaft berichten, dass die berichtenden Personen nach den in diesem Nachtrag Nr. 13 zu Schedule 13D beschriebenen Transaktionen zusammen wirtschaftliches Eigentum an 55,467,459 Aktien von Armata Pharmaceuticals, Inc. halten, was etwa 83,3% des Stammkapitals des Emittenten auf vollst盲ndig gez盲hlter Basis entspricht. Die Einreichung legt offen, dass Innoviva Strategic Opportunities LLC besicherte Verbindlichkeiten des Unternehmens im Rahmen eines Kreditvertrags vom 11. August 2025 erworben hat, der Armata ein $15,000,000-Termindarlehen bereitstellte.
Der Kreditvertrag vom August 2025 sieht einen Zinssatz von 14,00% per annum vor und l盲uft am 11. Januar 2029 ab; er ist ausdr眉cklich nicht wandelbar. Die berichtenden Personen halten weiterhin bestehende Stammaktien, Warrants zum Erwerb von zus盲tzlichen 10,653,847 Aktien sowie Rechte zum Erwerb von 19,736,843 Aktien bei Umwandlung eines wandelbaren Darlehens (ohne aufgelaufene Zinsen). Soweit hierin nicht ge盲ndert, bleiben fr眉here Angaben im Schedule 13D in Kraft.
- Reporting Persons beneficially own 55,467,459 shares, representing approximately 83.3% of outstanding common stock, establishing a clear majority economic stake.
- Innoviva Sub provided a secured $15,000,000 term loan to Armata under the August 2025 Credit Agreement, supplying liquidity to the issuer.
- The credit facility carries a 14.00% per annum interest rate, representing a relatively high cost of borrowing for the issuer.
- Reporting Persons' 83.3% beneficial ownership results in concentrated ownership, materially reducing the public float and limiting minority voting power.
Insights
TL;DR: Innoviva now holds a dominant economic and creditor position in Armata, supplying $15M liquidity under a secured loan.
The combined beneficial ownership of 55,467,459 shares (鈮�83.3%), together with warrants and a convertible-loan position, represents a controlling economic stake. The $15,000,000 secured term loan at 14.00% interest provides near-term liquidity to the issuer while establishing Innoviva Sub as a secured creditor until the January 11, 2029 maturity. For capital structure analysis, these items materially change Armata's equity float, creditor mix and potential governance dynamics; they are clearly material to valuation and liquidity assessments.
TL;DR: Concentrated ownership and related-party lending are material governance events that raise oversight and minority-interest considerations.
Reporting Persons' beneficial ownership of 83.3% is a significant governance development because it effectively consolidates voting control. The August 2025 Credit Agreement is a related-party secured loan at a 14.00% rate that is non-convertible, which changes creditor relationships without immediate dilution. Both facts are material to board dynamics and minority shareholder influence as presented in this filing.
Innoviva e la sua affiliata interamente controllata comunicano che, a seguito delle operazioni descritte nel presente Emendamento n. 13 al Schedule 13D, le persone che presentano la comunicazione detengono collettivamente la titolarit脿 effettiva di 55,467,459 azioni di Armata Pharmaceuticals, Inc., pari a circa 83,3% del capitale ordinario dell'emittente su base totalmente conteggiata. La comunicazione rivela che Innoviva Strategic Opportunities LLC ha acquisito debito garantito della societ脿 ai sensi di un contratto di credito dell'11 agosto 2025 che ha previsto un prestito a termine di $15,000,000 a favore di Armata.
L'Accordo di Credito di agosto 2025 prevede un tasso di interesse del 14,00% annuo e scade il 11 gennaio 2029, ed 猫 espressamente non convertibile. Le persone che presentano la comunicazione continuano a detenere le azioni ordinarie esistenti, warrant per l'acquisizione di ulteriori 10,653,847 azioni e diritti per acquisire 19,736,843 azioni al momento della conversione di un prestito convertibile (esclusi gli interessi maturati). Salvo quanto qui modificato, restano valide le precedenti divulgazioni nel Schedule 13D.
Innoviva y su filial de propiedad total informan que, tras las operaciones descritas en esta Enmienda n.潞 13 al Schedule 13D, las Personas Informantes poseen conjuntamente la propiedad beneficiaria de 55,467,459 acciones de Armata Pharmaceuticals, Inc., que representan aproximadamente 83,3% del capital social ordinario del emisor en base a recuento total. La presentaci贸n revela que Innoviva Strategic Opportunities LLC adquiri贸 deuda garantizada de la compa帽铆a en virtud de un contrato de cr茅dito de 11 de agosto de 2025 que otorg贸 a Armata un pr茅stamo a plazo de $15,000,000.
El Contrato de Cr茅dito de agosto de 2025 establece un tipo de inter茅s del 14,00% anual y vence el 11 de enero de 2029, y es expresamente no convertible. Las Personas Informantes contin煤an manteniendo acciones ordinarias existentes, warrants para adquirir 10,653,847 acciones adicionales y derechos para adquirir 19,736,843 acciones al convertir un pr茅stamo convertible (excluyendo intereses devengados). Salvo las enmiendas aqu铆 indicadas, permanecen vigentes las divulgaciones anteriores del Schedule 13D.
Innoviva鞕� 攴� 鞝勳暋 於滌瀽 瓿勳棿靷姅 氤� Schedule 13D鞚� Amendment No. 13鞐� 旮办灛霅� 瓯半灅鞐� 霐半澕 氤搓碃鞚胳澊 頃╆硠 55,467,459欤检潣 Armata Pharmaceuticals, Inc. 欤检嫕鞐� 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 氚滍枆須岇偓鞚� 氤错喌欤� 齑濎垬鞚� 鞎� 83.3%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� Innoviva Strategic Opportunities LLC臧� Armata鞐愱矊 $15,000,000鞚� 旮瓣皠雽�於滌潉 鞝滉车頃� 2025雲� 8鞗� 11鞚�鞛� 鞁犾毄瓿勳暯鞐� 霐半澕 須岇偓鞚� 雼措炒攵� 毂勲毳� 鞚胳垬頄堨潓鞚� 瓿奠嫓頃╇媹雼�.
2025雲� 8鞗� 鞁犾毄瓿勳暯鞚� 鞐办澊鞙� 14.00%毳� 鞝侅毄頃橂┌ 毵岅赴電� 2029雲� 1鞗� 11鞚�鞚搓碃 氇呾嫓鞝侅溂搿� 鞝勴櫂 攵堦皜鞛呺媹雼�. 氤搓碃鞚鸽摛鞚� 旮办〈 氤错喌欤�, 於旉皜搿� 10,653,847欤茧ゼ 旆摑頃� 靾� 鞛堧姅 鞗岆煱韸� 氚� 鞝勴櫂順� 雽�於滌潣 鞝勴櫂 鞁� 19,736,843欤茧ゼ 旆摑頃� 甓岆Μ(氚滌儩 鞚挫瀽 鞝滌櫢)毳� 瓿勳啀 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氤� 靾橃爼靹滌棎靹� 雼Μ 氤�瓴诫悳 攵�攵勳潉 鞝滌櫢頃橁碃電� 鞚挫爠鞚� Schedule 13D 瓿奠嫓電� 鞙犿毃頃╇媹雼�.
Innoviva et sa filiale en pleine propri茅t茅 signalent que, suite aux op茅rations d茅crites dans le pr茅sent Amendement n掳13 au Schedule 13D, les personnes d茅clarante d茅tiennent collectivement la propri茅t茅 b茅n茅ficiaire de 55,467,459 actions d'Armata Pharmaceuticals, Inc., repr茅sentant environ 83,3% des actions ordinaires de l'茅metteur sur une base enti猫rement comptabilis茅e. Le d茅p么t r茅v猫le qu'Innoviva Strategic Opportunities LLC a acquis des cr茅ances garanties de la soci茅t茅 en vertu d'un contrat de cr茅dit dat茅 du 11 ao没t 2025 qui a accord茅 脿 Armata un pr锚t 脿 terme de $15,000,000.
Le contrat de cr茅dit d'ao没t 2025 porte un taux d'int茅r锚t de 14,00% par an et arrive 脿 茅ch茅ance le 11 janvier 2029, et il est express茅ment non convertible. Les personnes d茅clarante conservent les actions ordinaires existantes, des warrants permettant d'acqu茅rir 10,653,847 actions suppl茅mentaires et des droits d'acqu茅rir 19,736,843 actions lors de la conversion d'un pr锚t convertible (hors int茅r锚ts courus). Sauf modification apport茅e par les pr茅sentes, les divulgations ant茅rieures au Schedule 13D restent en vigueur.
Innoviva und seine hundertprozentige Tochtergesellschaft berichten, dass die berichtenden Personen nach den in diesem Nachtrag Nr. 13 zu Schedule 13D beschriebenen Transaktionen zusammen wirtschaftliches Eigentum an 55,467,459 Aktien von Armata Pharmaceuticals, Inc. halten, was etwa 83,3% des Stammkapitals des Emittenten auf vollst盲ndig gez盲hlter Basis entspricht. Die Einreichung legt offen, dass Innoviva Strategic Opportunities LLC besicherte Verbindlichkeiten des Unternehmens im Rahmen eines Kreditvertrags vom 11. August 2025 erworben hat, der Armata ein $15,000,000-Termindarlehen bereitstellte.
Der Kreditvertrag vom August 2025 sieht einen Zinssatz von 14,00% per annum vor und l盲uft am 11. Januar 2029 ab; er ist ausdr眉cklich nicht wandelbar. Die berichtenden Personen halten weiterhin bestehende Stammaktien, Warrants zum Erwerb von zus盲tzlichen 10,653,847 Aktien sowie Rechte zum Erwerb von 19,736,843 Aktien bei Umwandlung eines wandelbaren Darlehens (ohne aufgelaufene Zinsen). Soweit hierin nicht ge盲ndert, bleiben fr眉here Angaben im Schedule 13D in Kraft.
FAQ
How much of ARMP does Innoviva beneficially own?
What financing did Innoviva provide to Armata (ARMP)?
What are the key economic terms of the August 2025 Credit Agreement?
Do Innoviva's holdings include warrants or convertible rights in ARMP?
Does the filing state any share purchases or sales in the last 60 days?
